Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2023
AbbVie announces acquisition of Cerevel Therapeutics
AbbVie announced it will acquire Cerevel Therapeutics for $45 per share in cash, valuing the drugmaker at about $8.7 billion. The transaction is subject to regulatory approvals, Cerevel shareholder approval and other customary closing conditions.
2023
Cerevel announces Ron Renaud as incoming CEO
Cerevel Therapeutics announced Ron Renaud’s appointment as president and CEO, effective June 12, 2023; Tony Coles will continue as board chairperson.
2020
Cerevel Therapeutics begins trading on Nasdaq
Cerevel Therapeutics began trading on the Nasdaq on October 28, 2020, after its business combination with Arya Sciences Acquisition Corp II. The article reports net proceeds of about $440 million from the transaction.